



---

## "TBI Miracle Drug" profiled in US pharmaceutical magazine

**Lund, Sweden — September 15, 2011** — A U.S. magazine called Pharmaceutical Formulation & Quality (circulation to 20,000 senior pharmaceutical executives throughout the US and Canada) has just published an article explaining cyclosporine and its potential as a traumatic brain injury (TBI) pharmaceutical. The article, entitled "Cyclosporine - TBI's Miracle Drug," is in the magazine's August/September 2011 issue. Subtitled: "An accidental discovery about 20 years ago has led to a cyclosporine pharmaceutical on the threshold of approval". The article explains the history of NeuroVive's initial research and the reasons why cyclosporine has such positive impact on TBI and reperfusion injury in myocardial infarction. The article can be read online at the magazine's website ([www.pharmaquality.com](http://www.pharmaquality.com)).

The article was authored by Steve Campbell, a writer and communication consultant in Vancouver, B.C., who writes for and about pharmaceutical and scientific research, products, and biotech companies. NeuroVive's CSO Eskil Elmér reviewed the article to ensure scientific accuracy.

### **About NeuroVive**

NeuroVive Pharmaceutical AB is a Swedish drug development company whose primary mission is to develop drugs for the treatment of acute brain injury, reperfusion injury in myocardial infarction and other acute injuries where mitochondrial energy production is critical for clinical outcome. The research and development program focuses on developing new variants of cyclophilin-D-inhibiting cyclosporins and studying ways of transporting these drugs across the blood-brain barrier to the central nervous system.

NeuroVive's shares are listed on the Swedish trading platform AktieTorget ([www.aktietorget.se](http://www.aktietorget.se)). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.

For further information contact:

Mikael Brönnegård, MD, CEO, NeuroVive Pharmaceutical AB

Telephone: +46 46 288 0110

Cell: +46 70 299 6264

E-mail: [mikael.bronnegard@neurovive.com](mailto:mikael.bronnegard@neurovive.com)

Web: [www.neurovive.com](http://www.neurovive.com)

Biomedical Center BMC D10, SE-221 84 Lund, Sweden